Cargando…
Monoclonal and Oligoclonal Anti-PF4 Antibodies Mediate VITT
Background: ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Janssen Johnson & Johnson) vaccines against COVID-19 have been associated with thrombotic thrombocytopenic reactions referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT) characterized by the presence of platelet-activ...
Autores principales: | Singh, Bandana, Kanack, Adam, Bayas, Antonios, George, Gemlyn, Abou-Ismail, Mouhamed Yazan Abou, Kohlhagen, Mindy, Christ, Monika, Naumann, Markus, Moser, Karen A, Smock, Kristi J, Grazioli, Alison, Murray, David L, Padmanabhan, Anand |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701560/ http://dx.doi.org/10.1182/blood-2021-153307 |
Ejemplares similares
-
Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT
por: Kanack, Adam J., et al.
Publicado: (2022) -
Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin
por: Singh, B, et al.
Publicado: (2021) -
Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
por: Kanack, Adam J., et al.
Publicado: (2022) -
Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2022) -
Deep Vein Thrombosis after COVID-19 Vaccinations
por: Houghton, Damon E., et al.
Publicado: (2021)